KIM
ESLA icon

Karpus Investment Management’s Estrella Immunopharma ESLA Stock Holding History

Karpus Investment Management’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-863,249
Closed -$8.87M – 384
2022
Q4 		$8.87M Sell
863,249
-21,902
-2% -$223K 0.3% 77
2022
Q3 		$8.9M Buy
885,151
+22,500
+3% +$226K 0.31% 72
2022
Q2 		$8.63M Sell
862,651
-100
-0% -$1K 0.29% 77
2022
Q1 		$8.62M Sell
862,751
-3,500
-0.4% -$34.9K 0.26% 89
2021
Q4 		$8.59M Buy
866,251
+87,851
+11% +$870K 0.25% 97
2021
Q3 		$7.71M Buy
+778,400
New +$7.66M 0.23% 98

Other funds holding ESLA

HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
SOA
Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Karpus Investment Management's ESLA Position: Q1 2023 in Review

Karpus Investment Management sold out of Estrella Immunopharma (ESLA) in Q1 2023, closing a stake of 863,249 shares — an estimated $8.87M sold.

Karpus Investment Management first reported a position in ESLA in Q3 2021 and held it in 6 quarters. The position peaked at $8.9M in Q3 2022. 8 funds tracked by Wall St. Rank hold ESLA as of Q1 2023.

  • Karpus Investment Management reported no remaining Estrella Immunopharma position as of Q1 2023 after selling out during the quarter.
  • Karpus Investment Management sold 863,249 Estrella Immunopharma shares in Q1 2023, an estimated $8.87M.
  • Karpus Investment Management first reported a position in Estrella Immunopharma in Q3 2021 and held it in 6 quarters.
  • Karpus Investment Management's Estrella Immunopharma position peaked at $8.9M in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2023.

Based on Karpus Investment Management's 13F filing for Q1 2023, filed 11 May 2023.